PeptidePedia The community reference

Contributions of SatietySunniva

User contributions·31 logged edits·page 1 of 1

Contributions by SatietySunniva, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,755 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 18,353 +860 m label the reception tally as weak, self-selected evidence at this point of use
  2. 03:08, 8 May 2026 (diff | hist) Glucose-dependent insulinotropic polypeptide 8,265 ±0 add see also to the sister hormone
  3. 03:15, 16 Mar 2026 (diff | hist) AmbioPharm 15,850 +798 fix hyphenation per PP:MOS
  4. 06:52, 7 Mar 2026 (diff | hist) Insulin secretion 6,940 ±0 add category for receptor pharmacology
  5. 10:20, 21 Jan 2026 (diff | hist) Talk:Satiety signalling 400 +167 /* Satiation versus satiety */ new section
  6. 17:09, 13 Jan 2026 (diff | hist) Proglucagon 6,709 ±0 the article treated a rodent finding as human physiology; corrected
  7. 10:33, 17 Dec 2025 (diff | hist) Arcuate nucleus 5,251 ±0 m add category for receptor pharmacology
  8. 00:22, 20 Nov 2025 (diff | hist) Enteroendocrine L cell 5,083 ±0 clarify that concentrations differ substantially between assay platforms
  9. 12:29, 16 Nov 2025 (diff | hist) Incretin effect 7,358 ±0 m split §Physiology from §Pharmacological exploitation
  10. 10:26, 30 Oct 2025 (diff | hist) Cagrilintide 4,256 ±0 fix a broken wikilink
  11. 20:31, 20 Oct 2025 (diff | hist) Incretin effect 7,358 ±0 m the half-life given was for the intact peptide; label it
  12. 20:25, 18 Sep 2025 (diff | hist) Underfilling 4,674 ±0 m add category for certificates of analysis
  13. 08:35, 28 Aug 2025 (diff | hist) Area percent purity 7,380 ±0 m clarify that mass spectrometry confirms identity, not purity
  14. 20:54, 22 Aug 2025 (diff | hist) Incretin effect 7,134 ±0 m add category for receptor pharmacology
  15. 18:55, 7 Jun 2025 (diff | hist) GLP-1 receptor 7,031 +361 ce per PP:MOS
  16. 08:24, 7 May 2025 (diff | hist) ChinaPeptides 8,933 +1,017 clarify that a registered business scope is a licensing fact, not a quality assurance
  17. 22:03, 16 Apr 2025 (diff | hist) Satiety signalling 4,441 ±0 m split overlong sentence
  18. 23:05, 20 Mar 2025 (diff | hist) Incretin effect 5,768 +343 the glucose-dependence of the insulinotropic effect deserves its own sentence
  19. 18:03, 15 Feb 2025 (diff | hist) GLP-1 receptor 6,105 +583 add a figure for the secretion time course and caption it
  20. 18:51, 6 Jan 2025 (diff | hist) Retention time 3,306 +374 expand §What it can identify
  21. 18:35, 2 Jan 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 5,045 +33 add the storage and handling guidance the organisation publishes
  22. 22:05, 14 Dec 2024 (diff | hist) Gastric emptying 3,976 +140 give the fasting and postprandial concentrations with the assay named
  23. 22:43, 21 Nov 2024 (diff | hist) GLP-1 receptor 5,187 +119 convert the receptor-distribution list to a table
  24. 00:43, 17 Nov 2024 (diff | hist) Glucagon-like peptide-1 8,227 +341 fix hyphenation per PP:MOS
  25. 17:29, 9 Nov 2024 (diff | hist) Albumin binding half-life extension 3,157 ±0 m attribute the receptor-density claim to the tissue study it comes from
  26. 12:47, 9 Nov 2024 (diff | hist) Dipeptidyl peptidase-4 4,168 +156 add see also to the sister hormone
  27. 00:10, 27 Oct 2024 (diff | hist) Glucagon-like peptide-1 7,886 +487 add the postprandial time course with its units
  28. 19:35, 14 Sep 2024 (diff | hist) Proglucagon 2,929 +227 the glucose-dependence of the insulinotropic effect deserves its own sentence
  29. 00:03, 29 Aug 2024 (diff | hist) Insulin secretion 2,360 ±0 m move the trial material out of §Physiology into the compound articles
  30. 09:00, 21 Aug 2024 (diff | hist) Beta cell function 1,687 +1,687 N start article on the hormone
  31. 22:03, 22 Jul 2024 (diff | hist) Dipeptidyl peptidase-4 2,323 ±0 m add the reference range with the assay it was established on